



Wiley Rein & Fielding LLP

1776 K STREET NW
WASHINGTON, DC 20006
PHONE 202.719.7000
FAX 202.719.7049

Virginia Office
7925 JONES BRANCH DRIVE
SUITE 6200
McLEAN, VA 22102
PHONE 703.905.2800
FAX 703.905.2820

www.wrf.com

June 19, 2006

David E. Hilliard
202.719.7058
dhilliard@wrf.com

VIA ELECTRONIC MAIL

Mr. Julius P. Knapp
Deputy Chief
Office of Engineering and Technology
Federal Communications Commission
Washington, DC 20554

Re: Raytheon Missile Systems Company
Request for Confidentiality
File No. 0385-EX-ST-2006

Dear Mr. Knapp:

Pursuant to Section 0.459 of the Commission's Rules, 47 C.F.R. § 0.459 (2005), I am requesting confidential treatment for the information set forth in the documents identified below. This request is supported by the following showing:

1. Identification of the specific information for which confidential treatment is sought:

The information is set forth in the slides entitled Overview of the Active Denial System that were shown to the FCC staff at our meeting on June 7, 2006, and recently updated. The information is also set forth in the copy of a letter dated April 4, 2005, from the Food and Drug Administration to the Chief for Health Effects Assessment of the Joint Non-Lethal Weapons Directorate concerning the demonstration of the Active Denial System ("ADS").

2. Identification of the Commission proceeding in which the information was submitted or a description of the circumstances giving rise to the submission:

The proceeding for which the information is submitted is that covered by file no. 0385-EX-ST-2006.

3. Explanation of the degree to which the information is commercial or financial or contains a trade secret or is privileged:

The slides and the letter set forth information that Raytheon treats as confidential business information. The information discusses key functional aspects of a long term project pertaining to the development of systems as part of a government program to employ RF energy to deter hostile conduct without resorting to potentially lethal force.

4. Explanation of the degree to which the information concerns a service that is subject to competition:

The information pertains to the development of non-lethal means for the deterrence of hostile conduct. This is a very competitive industry in which a variety of technologies have been deployed and are in development by many different companies. As noted in the application, the proposed operation concerns the use of millimeter wave technology for defense systems. The development of RF systems for this region is a highly competitive industry.

5. Explanation of how disclosure of the information could result in substantial competitive harm:

As noted above, the use of non-lethal approaches to deter hostile behavior from combatants and those acting unlawfully is a competitive field. In addition, the development of systems employing millimeter wave technology is competitive and requires a high degree of innovation. Premature disclosure of information currently held in confidence could allow others to benefit unfairly from the investment of Raytheon.

6. Identification of any measures taken by the submitting party to prevent unauthorized disclosure:

Raytheon protects the information through internal policies designed to keep proprietary information and other information subject to non-disclosure obligations confidential. These include the use of training, agreements regarding the use of information, and physically securing material containing confidential information.

7. Identification of whether the information is available to the public and the extent of any previous disclosure of the information to third parties:

Information concerning the general principles pertaining to active denial technology, which is employed in the application, is available through books, periodicals, and websites. However, the information set forth in the attached materials, which discusses an Active Denial System (the Silent Guardian™) as implemented by Raytheon is treated by Raytheon as confidential business information and is not publicly available except within Raytheon, its development partners, and the federal agencies associated with the development of the technology.

8. Justification of the period during which the submitting party asserts that material should not be available for public disclosure:

Raytheon requests that this information be accorded confidential treatment until such time as it is publicly disclosed by Raytheon or by those agencies associated with the development of the Silent Guardian™. The reason for the indefinite period of confidentiality is that it is not possible at this time to predict when the technology will be available for use by other than federal government entities, which would likely result in the public disclosure of some or all of the information. Nor does Raytheon have control over information controlled by federal government entities and denominated “for official use only.”

9. Any other information that the party seeking confidential treatment believes may be useful in assessing whether its request for confidentiality should be granted.

In addition, certain of the slides and, Raytheon understands, the letter from the FDA should be considered as available “for official use only,” disclosure of which would require additional approval from the federal agencies associated with the development of the Silent Guardian™. Finally, should the Commission deny the request for confidentiality, Raytheon respectfully requests that the documents identified in this request be returned in accordance with Section 0.459(e) of the Commission’s Rules, 47 C.F.R. §§ 0.459(e)(2005).

Wiley Rein & Fielding LLP

Mr. Julius P. Knapp

June 19, 2006

Page 4

Should any question arise concerning this matter, please contact me.

Respectfully,

/s/ David E. Hilliard

David E. Hilliard

Counsel for Raytheon Missile Systems Company

Attachments: Slides and FDA Letter

cc: Messrs. Keltz, Cleveland, Burtle, and Kennedy
Lauren Van Wazer, Esq.